vs
Mativ Holdings, Inc.（MATV）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
UNITED THERAPEUTICS Corpの直近四半期売上が大きい（$790.2M vs $463.1M、Mativ Holdings, Inc.の約1.7倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 21.8%、差は24.3%）。UNITED THERAPEUTICS Corpの前年同期比売上増加率が高い（7.4% vs 1.0%）。UNITED THERAPEUTICS Corpの直近四半期フリーキャッシュフローが多い（$173.3M vs $8.0M）。過去8四半期でUNITED THERAPEUTICS Corpの売上複合成長率が高い（8.0% vs -3.8%）
Mativ Holdings, Inc.は世界的な特殊材料メーカーで、高性能先端ポリマー、不織布、ろ過ソリューション、機能性コーティング材料を製造しています。医療、産業、消費財、航空宇宙、エネルギー分野に顧客を持ち、北米、欧州、アジア太平洋地域で事業を展開しています。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
MATV vs UTHR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $463.1M | $790.2M |
| 純利益 | $100.8M | $364.3M |
| 粗利率 | 18.8% | 86.9% |
| 営業利益率 | 2.2% | 45.1% |
| 純利益率 | 21.8% | 46.1% |
| 売上前年比 | 1.0% | 7.4% |
| 純利益前年比 | 6620.0% | 20.9% |
| EPS（希薄化後） | $1.87 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $463.1M | $790.2M | ||
| Q3 25 | $513.7M | $799.5M | ||
| Q2 25 | $525.4M | $798.6M | ||
| Q1 25 | $484.8M | $794.4M | ||
| Q4 24 | $458.6M | $735.9M | ||
| Q3 24 | $498.5M | $748.9M | ||
| Q2 24 | $523.8M | $714.9M | ||
| Q1 24 | $500.2M | $677.7M |
| Q4 25 | $100.8M | $364.3M | ||
| Q3 25 | $-3.2M | $338.7M | ||
| Q2 25 | $-9.5M | $309.5M | ||
| Q1 25 | $-425.5M | $322.2M | ||
| Q4 24 | $1.5M | $301.3M | ||
| Q3 24 | $-20.8M | $309.1M | ||
| Q2 24 | $-1.4M | $278.1M | ||
| Q1 24 | $-28.0M | $306.6M |
| Q4 25 | 18.8% | 86.9% | ||
| Q3 25 | 19.3% | 87.4% | ||
| Q2 25 | 19.7% | 89.0% | ||
| Q1 25 | 15.0% | 88.4% | ||
| Q4 24 | 16.9% | 89.7% | ||
| Q3 24 | 18.8% | 88.9% | ||
| Q2 24 | 20.8% | 89.1% | ||
| Q1 24 | 16.8% | 89.2% |
| Q4 25 | 2.2% | 45.1% | ||
| Q3 25 | 3.1% | 48.6% | ||
| Q2 25 | 3.8% | 45.6% | ||
| Q1 25 | -88.8% | 48.2% | ||
| Q4 24 | 0.6% | 48.6% | ||
| Q3 24 | 1.4% | 45.8% | ||
| Q2 24 | 2.0% | 44.7% | ||
| Q1 24 | -2.8% | 52.6% |
| Q4 25 | 21.8% | 46.1% | ||
| Q3 25 | -0.6% | 42.4% | ||
| Q2 25 | -1.8% | 38.8% | ||
| Q1 25 | -87.8% | 40.6% | ||
| Q4 24 | 0.3% | 40.9% | ||
| Q3 24 | -4.2% | 41.3% | ||
| Q2 24 | -0.3% | 38.9% | ||
| Q1 24 | -5.6% | 45.2% |
| Q4 25 | $1.87 | $7.66 | ||
| Q3 25 | $-0.06 | $7.16 | ||
| Q2 25 | $-0.18 | $6.41 | ||
| Q1 25 | $-7.82 | $6.63 | ||
| Q4 24 | $0.03 | $6.23 | ||
| Q3 24 | $-0.38 | $6.39 | ||
| Q2 24 | $-0.03 | $5.85 | ||
| Q1 24 | $-0.52 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $84.2M | $2.9B |
| 総負債低いほど良い | $1.0B | — |
| 株主資本純資産 | $498.7M | $7.1B |
| 総資産 | $2.1B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | 2.07× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $84.2M | $2.9B | ||
| Q3 25 | $97.1M | $2.8B | ||
| Q2 25 | $95.6M | $3.0B | ||
| Q1 25 | $84.0M | $3.3B | ||
| Q4 24 | $94.3M | $3.3B | ||
| Q3 24 | $162.2M | $3.3B | ||
| Q2 24 | $133.4M | $3.0B | ||
| Q1 24 | $128.9M | $2.7B |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $498.7M | $7.1B | ||
| Q3 25 | $397.4M | $6.6B | ||
| Q2 25 | $416.6M | $7.2B | ||
| Q1 25 | $428.2M | $6.8B | ||
| Q4 24 | $858.5M | $6.4B | ||
| Q3 24 | $882.3M | $6.1B | ||
| Q2 24 | $898.0M | $5.7B | ||
| Q1 24 | $906.9M | $5.3B |
| Q4 25 | $2.1B | $7.9B | ||
| Q3 25 | $2.0B | $7.4B | ||
| Q2 25 | $2.1B | $7.9B | ||
| Q1 25 | $2.1B | $7.7B | ||
| Q4 24 | $2.4B | $7.4B | ||
| Q3 24 | $2.6B | $7.1B | ||
| Q2 24 | $2.6B | $6.7B | ||
| Q1 24 | $2.7B | $6.5B |
| Q4 25 | 2.07× | — | ||
| Q3 25 | 2.63× | — | ||
| Q2 25 | 2.66× | — | ||
| Q1 25 | 2.67× | — | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | 1.30× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $19.3M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $8.0M | $173.3M |
| FCFマージンFCF / 売上 | 1.7% | 21.9% |
| 設備投資強度設備投資 / 売上 | 2.4% | 21.9% |
| キャッシュ転換率営業CF / 純利益 | 0.19× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | $93.8M | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $19.3M | $346.2M | ||
| Q3 25 | $72.8M | $562.1M | ||
| Q2 25 | $57.6M | $191.7M | ||
| Q1 25 | $-15.9M | $461.2M | ||
| Q4 24 | $24.1M | $341.2M | ||
| Q3 24 | $37.6M | $377.2M | ||
| Q2 24 | $46.1M | $232.2M | ||
| Q1 24 | $-13.0M | $376.5M |
| Q4 25 | $8.0M | $173.3M | ||
| Q3 25 | $66.7M | $351.6M | ||
| Q2 25 | $48.9M | $129.5M | ||
| Q1 25 | $-29.8M | $386.3M | ||
| Q4 24 | $2.0M | $254.5M | ||
| Q3 24 | $25.5M | $300.7M | ||
| Q2 24 | $37.4M | $187.1M | ||
| Q1 24 | $-25.1M | $338.3M |
| Q4 25 | 1.7% | 21.9% | ||
| Q3 25 | 13.0% | 44.0% | ||
| Q2 25 | 9.3% | 16.2% | ||
| Q1 25 | -6.1% | 48.6% | ||
| Q4 24 | 0.4% | 34.6% | ||
| Q3 24 | 5.1% | 40.2% | ||
| Q2 24 | 7.1% | 26.2% | ||
| Q1 24 | -5.0% | 49.9% |
| Q4 25 | 2.4% | 21.9% | ||
| Q3 25 | 1.2% | 26.3% | ||
| Q2 25 | 1.7% | 7.8% | ||
| Q1 25 | 2.9% | 9.4% | ||
| Q4 24 | 4.8% | 11.8% | ||
| Q3 24 | 2.4% | 10.2% | ||
| Q2 24 | 1.7% | 6.3% | ||
| Q1 24 | 2.4% | 5.6% |
| Q4 25 | 0.19× | 0.95× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | 16.07× | 1.13× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 0.83× | ||
| Q1 24 | — | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
